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Abstract 
Developing therapies for neurodegenerative diseases will require new scientific approaches 
that takes into account the complex multicellular interactions  of the nervous system.  
 
 
 
Introduction 
 
The growing incidence of neurodegenerative diseases is a ticking time bomb. In addition to the 
toll these conditons take on patients and caregivers, their drain on the global economy is huge.  
Alzheimer’s disease, the most common neurodegenerative disorder, affects one in nine people 
over the age of 65 and accounts for more than 60% of dementia worldwide. The global cost of 
Alzheimer’s disease and dementia is projected to hit $1 trillion by 2018 
(http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf ). In the United States, 
currently Alzheimer’s disease affects 5.4 million people and this is expected to triple by 2050. 
Other neurodegenerative diseases, although not as common, are no less debilitating.  
 
In the face of great clinical need, however, there has been little success in developing effective 
therapies for neurodegenerative diseases. Between 2002 and 2014, 413 clinical trials assessing 
214 compounds to treat Alzheimer’s disease yielded just one new approval by the US Food and 
Drug Administration (FDA) — a success rate of 0.4% (2). No new treatments have been 
approved since 2003. Other neurodegenerative diseases have fared no better. Even for those 
with a defined monogenic etiology, such as Huntington’s disease, no treatment exists that 
meaningfully modifies disease progression. 
 
As researchers develop an in-depth understanding of the basic mechanisms underlying 
neurodegeneration,  the interrelation of a number of these disorders is becoming clear. 
Breaking the therapeutic stalemate will require multidisciplinary and combinatorial approaches, 
as well as the long-term engagement of all players involved. The high costs of developing new 
medications necessitate careful consideration of how to best use the available resources, as 
well as how to build more productive collaborations between industry, academia and public 
organizations. Equally important will be the social dimensions surrounding neurodegenerative 
disease research and policy, such as public awareness, breaking the taboo around dementia, 
public education, implementation of preventative measures, and getting sufficient support for 
research.  
 
In April this year, more than 400 people assembled at Baylor College of Medicine to address 
these challenges at the third biennial symposium of the Jan and Dan Dunan Neurological 
Research Institute. Attendees and speakers consisted of academic researchers conducting basic 
mechanistic studies on neurodegeneration, clinicians at the front line of patient care, 
pharmaceutical company scientists working on translating basic research discoveries into 
effective therapies, foundations and government agencies that support research, as well as  
patients and advocates. This diverse group identified research priorities and stressed the 
importance of embracing data sharing and more inclusive publishing models. 
 
 
Snapshots of Neurodegenerative Disease  
 
The proteinopathies: Accumulation, seeding and aggregation. 
 
Several neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, 
Huntington’s disease, frontotemporal dementia, and Spinocerebellar Ataxia type 1 are so-called 
proteinopathies, characterized by misfolding, accumulation, and aggregation of a specific 
disease-driving protein. The appearance of these aggregates correlates to different extents with 
disease pathogenesis. A clear understanding of the mechanisms underlying the potential 
pathogenicity of protein aggregates is still lacking, however.  
 
A common theme throughout many neurodegenerative disorders is the appearance  and 
spreading of abnormal protein aggregates throughout the brain . One hypothesis postulates 
that initial protein aggregates that are formed because proteins such as alpha-synuclein, Tau, 
amyloid-β can adopt an abnormal conformation. Such abnormal conformers can, once 
generated,  act as “seeds”  that somehow convert normal protein into a pathological state. 
Many researchers are exploring how such seeding occurs. For example, recent work has shown 
that  the tau protein that cause distinct tauopathies, folds in different pathological 
conformations, which trigger different aggregation patterns. At the moment only biological 
assays are available that can follow this phenomenon, i.e. it can be demonstrated  that these 
different Tau conformers, when seeded in cultured cells expressing tau, induce the  
propagation of different “strains” of  abnormal Tau aggregates (3). Furthermore, when these 
different tau species were re-inoculated into the brains of transgenic mice expressing mutant 
human tau protein, they induced different  tau pathologies that resembled the aggregate 
patterns seen in patients with tauopathies (4, 5). This suggests that individual tauopathies are 
associated with unique “strains” of the tau protein and provides an avenue for investigating 
how a single protein pathology can yield multiple disease phenotypes. In other work, neurons 
differentiated from patient-derived induced pluripotent stem cells carrying tauopathy-
associated mutations showed earlier electrophysiological maturation, altered mitochondrial 
transport, and early alterations in Tau splicing or Tau distribution before tau began to 
aggregate, pointing to an aggregation-independent aspect of the  pathogenesis (6).  Questions 
such as which tau assemblies seed further propagation, whether they exert cell-specific toxicity 
and what makes these assemblies toxic are under investigation.    
 
In detailed molecular studies of another neurodegenerative proteinopathy, the autosomal 
genetic disease spinocerebellar ataxia type 1 (SCA1), several complementary strategies are 
being explored to lower the mutant disease-causing protein, Ataxin-1. In one approach, 
unbiased genetic screens were used to identify genes that modulate expression of mutant 
Ataxin-1 (7). Running parallel screens in human cells and flies unveiled components of the 
RAS/MAPK/MSK1 signaling pathway that, when downregulated, reduced expression of mutant 
Ataxin-1 and partially ameliorated neurodegeneration. The therapeutic potential of these 
targets is currently being explored in preclinical studies using small molecule inhibitors against 
key mediators of this pathway. An alternative approach is to use antisense oligonucleotides 
(ASOs) to target the disease-driving protein. ASOs directly targeting mutant and wildtype alleles 
of Ataxin-1 transcripts in a mouse model of SCA1, for example, increased survival and 
ameliorated SCA1 pathology. This strategy is also being explored in monogenic disorders such 
as amyotrophic lateral sclerosis (ALS) and Huntington’s disease, for which ASOs targeting the 
disease-driving protein are already in clinical trials. The development of ASO and related 
therapies allows to test  very direcly therapeutic strategies that are based on genetic insights. It 
is likely that such approaches will become very important next to more 
classicalpharmacological strategies for the treatment of  diverse  neurodegenerative disorders 
(8,9).  
 
Altered RNA homeostasis  
Most genetic studies of neurodegenerative diseases have focused on identifying protein coding 
variants that lead to changes in protein function. Although many causes of Mendelian disorders 
have been identified with this strategy, genetic risk factors for more complex common diseases 
have been a greater challenge to define comprehensively, and even with large amounts of 
genomic sequencing of exonic variants, much missing heritability remains. A complementary 
way forward is to look for variation beyond the coding sequence, including assessment of 
variants that alter gene expression at the level of RNA regulation. Post-transcriptional processes 
such as alternative splicing, mRNA localization and translational regulation within different 
cellular compartments are key regulators of brain function and disturbed RNA homeostasis has 
been implicated in a number of  neurodegenerative disease pathologies.  
 
Mammalian neurons have unique systems of regulating RNA metabolism, mediated by several 
RNA binding proteins (RBPs) that are not expressed in any other cell type (10). These proteins 
regulate RNA at multiple levels, most clearly defined through regulation of splicing of 
transcripts that encode multiple functional properties of neurons. For example, differential 
splicing via one group of neuron-specific RBPs, neuron Elav-like (nElavl), maintains glutamate 
production and thereby contributes to the control of excitation and inhibition in the brain (11). 
Using a genome-wide in situ crosslinking assay (CLIP) to map specific points of nELAVL 
regulation, Scheckel et al (12) found that nELAVL bound transcripts of multiple genes implicated 
in neurodegenerative diseases. In postmortem brain tissue from Alzheimer’s disease patients , 
nELAVL showed increased binding to the Y non-coding RNA subset (hY3 RNAs), which have been 
linked to the stress response. The sequestration of nELAVL by this intronic transcript may 
represent a mechanism by which genetic variation in noncoding regions of the genome may be 
traced back to changes in splicing and ultimately to phenotypic changes in neurodegenerative 
disease.  
 
 
Several neurodegenerative diseases including ALS, frontotemporal dementia, and inclusion 
body myopathy show clinical, pathological, and genetic overlap. Underlying mechanisms are 
related to ubiquitin-dependent autophagy and RNA biology, suggesting an avenue for exploring 
therapeutic targets in pathways shared by multiple diseases. One such shared pathway is the 
functional impairment of membrane-less organelles, including nucleoli, stress granules and RNA 
transport granules. In the last year, studies from multiple labs have found that membrane-less 
organelles are assembled by liquid-liquid phase transitions of RNA-binding proteins that harbor 
low complexity sequence domains (13). Whereas membrane-less organelles are biologically 
advantageous, persistent assembly of low complexity domains in a highly concentrated liquid 
state risks further phase transition to pathological fibrils. Studies of the RNA-binding proteins 
hnRNPA2B1 and hnRNPA1, for example, suggest that mutations in low complexity sequence 
domains of these proteins alter the balance of this phase transition, leading to the fibrillar 
protein pathology characteristic of ALS (14). Given that  phase transitions are reversible, these 
insights suggest a therapeutic strategy based on tipping the balance in favor of disassembly. 
 
The role of glia and inflammation  
 
Tau, amyloid precursor protein (the cleavage of which generates amyloid- peptide), and other 
aggregate-prone proteins such as -synuclein are expressed in neurons, but research is now 
showing that non-neuronal cells such as glia are also involved in neuronal injury and cell death. 
Increasingly, neurodegenerative diseases are being treated less like  neuro-centric diseases and 
more like multi-cellular  diseases.  
 
Until recently, just one major genetic risk factor  for sporadic AD was known: the APOE gene 
where the 4 allele increases risk for AD and the ε2 allele decreases risk. ApoE’s effect on AD is 
thought to occur partly through modulating A aggregation and clearance. Interestingly, APOE 
is mainly expressed in glia  cells in the brain, calling attention to non-neuronal cell involvement 
in AD. Three years ago, researchers reported that rare mutations in the TREM2 gene, which is 
also mainly expressed in  non-neuronal cells, i.e. the   brain microglial cells, are also associated 
with a 2 to 4-fold increase in AD risk (15). Research investigating the biology of TREM2 points to 
a possible role for this receptor in modulating the brain’s response to protein aggregation by 
enabling microglial cells to contain neuritic damage (16-18). APOE and TREM2 may thus 
represent a link between Aβ aggregation, toxicity,  and the clinical presentation of AD.  
In another example of the importance of non-neuronal cells, astrocytes derived from people 
with ALS causing mutations in SOD1 trigger motor neuron death, presumably through the 
release of a toxic factor (19).  Genome-wide expression and proteomic analyses were used to 
identify the astrocyte-mediated toxic signal (20).  
These three  examples highlight the potential role of non-neuronal cells in neurodegeneration, 
and reveals likely a prospective source of therapies and new biomarkers (see for instance 21).   
 
Another intriguing dimension in neurodegenerative disease pathology is the role of 
neuroinflammation. New evidence has emerged for involvement of the  innate immune system 
in Parkinson’s disease. The two classes of major histocompatibility complex (MHC) molecules 
allow the immune system to recognize self and foreign peptides. MHC classI molecules, which 
tag antigens for identification by cytotoxic T  cells, are expressed by  most cell types, but they 
have generally not been thought to be expressed in the mammalian central nervous system. 
However, recent research has identified MHC class1 expression in rodent and human brain 
tissue, raising the possibility that neurons expressing MHC class1 could be selectively targeted 
for immune system destruction. 
 
In 2014, Cebrián et al (22) reported that MHC classI molecules are  expressed in catecholamine-
expressing neurons in the substantia nigra, and that this expression can be induced by 
microglial activity.  One could  speculate that microglial activation spurred by the death of 
dopaminergic neurons in Parkinson’s disease may upregulate neuronal MHC class I expression 
and display of antigens. If some sort of peripheral insult simultaneously leads to T lymphocytes 
breaching the blood brain barrier, those T cells could target and kill the antigen-expressing 
neurons. If this scenario is borne out, immunosuppressive therapeutic strategies used for 
treating  autoimmune disorders may be applicable to Parkinson’s disease, and perhaps other 
neurodegenerative diseases.  
 
Cellular organelles and neurodegeneration  
Much evidence points to a functional impairment of lysosomes – the cytoplasmic organelles 
responsible for clearing cellular debris – in the pathogenesis of multiple neurodegenerative 
diseases. Lysosomes are primarily known for their role as cellular incinerators, to which 
extracellular materials are transported through  endocytosis and intracellular materials are 
delivered through autophagy. Genetic disruptions in lysosomal function are known to cause 
more than 50 rare, debilitating multisystem disorders collectively called lysosomal storage 
diseases. Many of these diseases have a neurodegenerative component, and many disease-
causing genes in lysosomal storage diseases have also been linked to neurodegenerative 
disease. For example, whereas homozygous mutations in the gene encoding the enzyme 
glucocerebrosidase cause Gaucher’s disease, heterozygous mutations for the same gene are 
one of the strongest genetic risk factors for Parkinson’s disease (23).  
 
Indeed, recent work suggests that lysosomal and autophagy dysfunction are key mechanisms 
underlying the defective cellular clearance and accumulation of neurotoxic proteins 
characteristic of many neurodegenerative diseases such as AD, Parkinson’s disease, and 
Huntington’s disease. Traditionally, the lysosome has been viewed as a static organelle that is 
not subject to regulation. However, work published in 2009 identified a lysosomal gene 
network and its master regulator gene, TFEB, that controls lysosomal biogenesis and function in 
response to environmental cues (24). Further work showed that TFEB also regulates autophagy, 
mechanistically linking the delivery of materials to the lysosome through  that process with 
their degradation (25). Activating TFEB in neurodegenerative disease mouse models rescued 
the disease phenotype, suggesting that targeting this network may represent a new therapeutic 
strategy for treating these conditions (26). 
 
Dysfunction in another organelle, the mitochondrion, has long been implicated in the 
pathogenesis of Parkinson’s disease. Dopaminergic neurons, which are vulnerable in 
Parkinson’s disease, are especially sensitive to mitochondrial dysfunction. For instance, 
neurotoxins causing Parkinson’s disease-like symptoms are thought to block mitochondrial 
respiratory chain activity. Moreover, several genes in which mutations are causative for the 
disease are associated with mitochondrial function both in genetic and sporadic cases of the 
disease. For example, PINK1 mutations, associated with early  onset Parkinson’s disease, 
dysregulate mitochondrial function by interfering with the electron transport chain and 
mitochondrial membrane potential (27). Several molecules including Vitamin K2 rescue this 
deficit (28) and are being investigated in  preclinical studies. Other research shows that Pink1’s 
normal function is to recruit autophagy markers. In contrast, Parkin — encoded by a gene that 
also causes early onset Parkinson’s disease when mutated—amplifies the Pink1 mitophagy 
signal, thereby protecting endogenous neurons from mitochondrial dysfunction (29, 30). A 
better understanding of the role played by mitochondria in Parkinson’s disease might also shed 
some light on pathological processes of AD  and ALS, in which mitochondrial dysfunction is 
often present. 
 
 
Recommendations for the field 
 
 Multi-disciplinarity, integration, and data sharing 
 
Available animal models fall short in mimicking neurodegenerative processes in humans. 
Moreover, too many investigators work blindly and competitively alongside each other rather 
than collaborating. There needs to be integration of data from many different animal models, 
and integration of animal data with  patient-based research. Data sharing of both positive and 
negative data  between different research groups across industry and academia is also crucial. 
These efforts are especially important for pre-clinical research, where too much information 
currently remains buried in individual laboratories.   
  
One important way forward is to promote transparency about inconsistent results or problems 
with  data reproducibility. Scientists in academia and industry should publish data when they 
find  an inability to reproduce published results.  Industry scientists should  also share more 
readily insights about flawed studies with academic investigators. Moreover, granting agencies 
should encourage and support research groups to reproduce hallmark findings.  Lastly, journals 
need to be willing to dedicate a section of their journal for publishing such data. 
 
Another important bottleneck impeding  progress is the slow dissemination of results. Two 
robust solutions were proposed: first the creation of rapid publication journals that make 
information available faster in an open access format, and that would also publish genetic 
screens, large data sets, and, crucially,negative data.  The second suggestion was to provide 
alternative ways to give authorship credit to investigators and their groups when they generate 
and make available a large biological dataset, therefore eliminating the need to wait for 
publication before making the data available. 
 Alongside the great need for data sharing and integration, it is important to acknowledge the 
distinct roles played by academic research and industry. Whereas  academics are the driving 
force behind mechanistic characterization and identification of potential therapeutic avenues, 
the pharmaceutical industry is better resourced and positioned to conduct high powered 
studies and to identify chemical agents that could be developed into therapies. Government  
agencies should prioritize funding biology rather than chemical screens and clinical trials; 
meanwhile, industry should establish partnerships with academic labs to gain access to new  
scientific approaches that could then be  developed into therapies for testing in  clinical trials. 
 
New approaches to understand neurodegenerative disease 
 
A full understanding of neurodegenerative disease biology will require broadening our strictly 
neurocentric viewpoint. Cutting edge techniques that probe the role of non-neuronal cell 
types– for example, using genetic approaches to study the contribution of glial cells to neuronal 
networks -- should be more widely implemented to address questions such as how the diverse 
array of cellular interactions in the brain goes astray in different diseases. Single cell approaches 
are needed to better understand the contribution of individual cells to molecular and functional 
neuronal networks.  
 
It will also be important to expand the research focus beyond disease conditions and to develop 
a better understanding of the mechanisms underlying healthy aging. Such an approach could 
open the door to therapeutic strategies that build on molecular processes that bolster the 
brain’s resilience to damage accrued during aging.  A focus on identifying genetic modifiers 
present in healthy long-lived individuals and populations could be an initial step in this 
direction. 
 
Hypothesis-driven approaches have limitations but are the norm in the way public bodies 
prioritize their funding. The US National Institutes of Health (NIH) and other funding agencies 
should acknowledge the importance of screening methods and unbiased, not necessarily 
hypothesis driven approaches to explore new areas of biology relevant to neurodegenerative 
disease.  
 
Learning from the cancer field 
 
Therapeutic development in the cancer field has shown that there is no such thing as a magic 
bullet cure  and that multi-level approaches are needed. Very likely, the treatment of 
neurodegenerative disorders will consist of combinatorial therapies and also may be based on 
personalized genomics. A major issue complicating therapeutic development is the need for 
chronic treatment in neurodegenerative conditions: the issues of cost and of potential side 
effects are much more important for the neurodegenerative field than for most other fields of 
medicine that warrant in many cases shorter courses of therapy.  
 
Chances for young investigators 
 
The importance of training and mentoring young scientists and helping them to establish their 
careers is paramount to continued development of neurodegenerative disease research. 
Seasoned principal investigators should open the door (and also specifically their own doors) 
for their younger colleagues. The funding systems should more actively incentivize and reward  
young investigators who participate in interdisciplinary partnerships that address major 
questions or  solve major problems. Arguably,  the need to promote early-career scientists is 
even more pressing for female researchers, who continue to be vastly underrepresented at 
higher levels of the academic ladder and on research governing boards. Directed efforts at 
leveling the playing field and ensuring a fair representation are an immediate priority.   
 
Optimism for the future 
Despite the harsh assessment of therapeutic progress to date, prospects for developing 
therapies to treat neurodegenerative diseases are improving. New molecular and imaging 
techniques are providing  researchers with unprecedented tools to study disease mechanisms 
and assess the efficacy of experimental compounds., Public perception has generally held 
dementia to be an inevitable consequence of aging, but the accumulation of research 
demonstrating that it is a pathological state — and in theory, at least, a treatable one — is 
turning the tide of negative and fatalistic thinking with regard to these diseases in society.  
Funding for neurodegenerative disease research is at an all-time high. Five years ago, the 
United States launched an ambitious AD initiative and this year research on AD and related 
dementias received a historic $320 million increase in federal funding. Several large-scale brain 
research projects have been launched in the past few years,  most notably the three-year-old 
BRAIN Initiative, a US public-private partnership with some $500 million in funding this year 
that aims to develop the tools to decode the mysteries of the brain in health and disease. 
Meanwhile, pharmaceutical companies, which have shied away from neurological indications 
for the past decade, are cautiously returning to the field. These optimistic developments signal 
an ideal moment for neurodegenerative disease researchers to take stock of the field, identify 
the gaps in knowledge and challenges in addressing them, and map out how to most efficiently 
enable discoveries that can potentiate the development of new therapies for treating these 
devastating conditions.  
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Figure Legend 
The major cellular and molecular processes contributing to neurodegeneration. There are multiple 
processes that drive neurodegeneration as a result of specific genetic vulnerabilities or aging. Such 
processes include abnormally altered expression of some disease driving RNAs and proteins, dysfunction 
of specific cellular organelles such as mitochondria or lysosomes, neuroinflammation and altered 
responses of glia in the brain. Lysosomes and mitochondria are shown in purple and red, respectively. 
Abnormal protein accumulation and altered RNA-protein interactions are depicted as black spots. 
 
 
